An extremely delayed cytogenetic response to interferon-α in a patient with chronic myeloid leukaemia

Leukemia

Volumn 11, Issue 4, 1997, Pages 614-616

  Whiteway, A J ^a   Reid, C D L ^a   Cross, N C P ^b  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Chronic myeloid leukaemia; Interferon ; Philadelphia chromosome

Indexed keywords

ALPHA INTERFERON; ALPHAN1 INTERFERON; BUSULFAN;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG RESPONSE; FLU LIKE SYNDROME; HUMAN; LEUKEMIA REMISSION; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0030906077     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400622     Document Type: Article

References (12)

1. Goldman JM. Management of chronic myeloid leukaemia. Blood Rev 1986; 1: 21-29.
2. Kumar L, Gulati S. Alpha-interferon in chronic myelogenous leukaemia. Lancet 1995; 346: 984-985.
3. Talpaz M et al. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukaemia. Blood 1983; 62: 689-692.
4. Hochhaus A et al. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α. Br J Haematol 1995; 91: 126-131.
5. Hochhaus A et al. Quantification of residual disease in chronic myelogenous leukaemia patients on interferon-a therapy by competitive polymerase chain reaction. Blood 1996; 87: 1549-1555.
6. Allan NC et al. UK MRC randomised, multicentre trial of IFN-αn1 for CML: improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-1397.
7. Ozer H et al. Prolonged subcutaneous administration of recombinant α2b Interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukaemia: effect on remission duration and survival: Cancer and Leukaemia Group B Study 8583. Blood 1993; 82: 2975-2984.
8. Italian Cooperative Study Group on CML. Interferon α-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukaemia. New Engl J Med 1994; 330: 820-825.
9. Hehlmann R et al. Randomised comparison of interferon-α with busulphan and hydroxyurea in chronic myelogenous leukaemia. Blood 1994; 84: 4064-1077.
10. Kantarjian HM et al. Prolonged survival in chronic myelogenous leukaemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995; 122: 254-261.
11. Schofield JR et al. Low doses of IFN-α are as effective as higher doses in inducing remissions and prolonging survival in CML. Ann Intern Med 1994; 121: 736-744.
12. Cross N et al. Competitive PCR to estimate the number of bcr-abl transcripts in CML after bone marrow transplantation. Blood 1993; 82: 1929-1936.